{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:31:24Z","timestamp":1774337484776,"version":"3.50.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The purpose of this case report is to present a successful approach for the depletion of B cells and plasma cells in a highly sensitized patient prior to kidney transplantation using obinutuzumab, as well as to evaluate the potential of obinutuzumab in desensitization as an alternative to rituximab in cases of rituximab-induced anaphylaxis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Kidney transplantation stands as the gold standard treatment for end-stage kidney disease, offering improved quality of life and longevity. Living donor kidney transplantation is preferred over deceased donor transplantation due to its superior outcomes, but immunological barriers, such as human leukocyte antigen sensitization and ABO blood type incompatibility, remain significant challenges. This study explores desensitization strategies and emerging therapies to overcome these barriers to achieve successful ABO-incompatible kidney transplantation. We present the case of a 32-year-old woman with end-stage kidney disease secondary to systemic lupus erythematosus who was awaiting a living unrelated donor ABO-incompatible kidney transplantation. Due to elevated isoagglutinin titers, the patient underwent a desensitization treatment with rituximab, to which she had a severe anaphylactic reaction. Consequently, desensitization was completed with obinutuzumab (off-label use). The patient successfully underwent kidney transplantation with adequate isoagglutinin levels and without rejection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Desensitization strategies, including B-cell depletion with obinutuzumab, played a crucial role in achieving successful kidney transplantation in a highly sensitized patient. This case underscores the importance of personalized approaches and ongoing research aimed at overcoming immunological barriers to kidney transplantation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf300","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:39:07Z","timestamp":1761745147000},"page":"e246-e252","source":"Crossref","is-referenced-by-count":0,"title":["Obinutuzumab for B-cell depletion prior to kidney transplant in a highly sensitized patient with anaphylactic reaction to rituximab"],"prefix":"10.1093","volume":"83","author":[{"given":"Thais","family":"Lizondo","sequence":"first","affiliation":[{"name":"Pharmacy Service, Division of Medicines, Hospital Cl\u00ednic Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iria","family":"Carro","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Division of Medicines, Hospital Cl\u00ednic Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0845-8107","authenticated-orcid":false,"given":"Carla","family":"Bastida","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Division of Medicines, Hospital Clinic Barcelona, Barcelona, and Department of Pharmacology, Toxicology and Chemical Therapeutics. School of Pharmacy and Food Sciences. University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"Monge-Escart\u00edn","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Division of Medicines, Hospital Clinic Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Charry","sequence":"additional","affiliation":[{"name":"Hematology Service, Hemotherapy and Apheresis Section, Clinical Institute of Hematological and Oncological Diseases, Hospital Clinic Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2593-833X","authenticated-orcid":false,"given":"Miquel","family":"Lozano","sequence":"additional","affiliation":[{"name":"Hematology Service, Hemotherapy and Apheresis Section, Clinical Institute of Hematological and Oncological Diseases, Hospital Clinic Barcelona, Barcelona, and Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS) , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Gelis","sequence":"additional","affiliation":[{"name":"Allergy Service, Hospital Clinic Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Revuelta","sequence":"additional","affiliation":[{"name":"Hematology Service, Hemotherapy and Apheresis Section, Clinical Institute of Hematological and Oncological Diseases; and Kidney Transplant Unit, Department of Nephrology and Kidney Transplant, Hospital Clinic , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Soy","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Division of Medicines, Hospital Clinic Barcelona, Barcelona, and Department of Pharmacology, Toxicology and Chemical Therapeutics, School of Pharmacy and Food Sciences, University of Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"2","key":"2026032401014230900_zxaf300-B1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1053\/j.ajkd.2005.10.012","article-title":"The impact of accepting living kidney donors with mild hypertension or proteinuria on transplantation rates","volume":"47","author":"Karpinski","year":"2006","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2026032401014230900_zxaf300-B2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.5500\/wjt.v10.i7.191","article-title":"Current protocols and outcomes of ABO-incompatible kidney transplantation","volume":"10","author":"Salvadori","year":"2020","journal-title":"World J Transplant"},{"issue":"12S","key":"2026032401014230900_zxaf300-B3","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1097\/01.tp.0000296017.44394.e2","article-title":"ABO antigen expression in graft tissue: is titration against donor erythrocytes relevant?","volume":"84","author":"Rydberg","year":"2007","journal-title":"Transplantation"},{"issue":"3","key":"2026032401014230900_zxaf300-B4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1600-6143.2009.03001.x","article-title":"Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols","volume":"10","author":"Montgomery","year":"2010","journal-title":"Am J Transplant"},{"issue":"2","key":"2026032401014230900_zxaf300-B5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/TP.0000000000000959","article-title":"The challenge of acute antibody-mediated rejection in kidney transplantation","volume":"100","author":"Chehade","year":"2016","journal-title":"Transplantation"},{"key":"2026032401014230900_zxaf300-B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ajt.14584","article-title":"Antibody-mediated rejection: new approaches in prevention and management","volume":"18","author":"Montgomery","year":"2018","journal-title":"Am J Transplant"},{"issue":"4","key":"2026032401014230900_zxaf300-B7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.smim.2011.08.021","article-title":"Humoral immunity and antibody-mediated rejection in solid organ transplantation","volume":"23","author":"Montgomery","year":"2011","journal-title":"Semin Immunol"},{"issue":"11","key":"2026032401014230900_zxaf300-B8","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1681\/ASN.V8111771","article-title":"Effect of anti-lymphocyte induction therapy on renal allograft survival","volume":"8","author":"Szczech","year":"1997","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2026032401014230900_zxaf300-B9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/BF00353819","article-title":"The hyperimmunized patient: from sensitization toward transplantation","volume":"1","author":"Claas","year":"1988","journal-title":"Transpl Int"},{"issue":"11","key":"2026032401014230900_zxaf300-B10","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1111\/ajt.15514","article-title":"Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant","volume":"19","author":"Redfield","year":"2019","journal-title":"Am J Transplant"},{"issue":"6","key":"2026032401014230900_zxaf300-B11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5500\/wjt.v9.i6.103","article-title":"Therapeutic apheresis in kidney transplantation: an updated review","volume":"9","author":"Salvadori","year":"2019","journal-title":"World J Transplant"},{"issue":"8","key":"2026032401014230900_zxaf300-B12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.2215\/CJN.00540118","article-title":"ABO-incompatible kidney transplant outcomes","volume":"13","author":"de Weerd","year":"2018","journal-title":"Clin J Am Soc Nephol"},{"issue":"10185","key":"2026032401014230900_zxaf300-B13","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(18)32091-9","article-title":"Clinical outcomes after ABO-incompatible renal transplantation: a systematic review and meta-analysis","volume":"393","author":"Scurt","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"2026032401014230900_zxaf300-B14","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/phar.1426","article-title":"Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options","volume":"34","author":"Kim","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"9","key":"2026032401014230900_zxaf300-B15","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1097\/01.tp.0000261113.30757.d1","article-title":"Rituximab therapy for acute humoral rejection after kidney transplantation","volume":"83","author":"Faguer","year":"2007","journal-title":"Transplantation"},{"issue":"1","key":"2026032401014230900_zxaf300-B16","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1186\/s12885-022-09772-1","article-title":"Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma","volume":"22","author":"Lara","year":"2022","journal-title":"BMC Cancer"},{"issue":"4","key":"2026032401014230900_zxaf300-B17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/01.TP.0000112934.12622.2B","article-title":"Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. safety, pharmacodynamics, and pharmacokinetics","volume":"77","author":"Vieira","year":"2004","journal-title":"Transplantation"},{"issue":"11","key":"2026032401014230900_zxaf300-B18","doi-asserted-by":"publisher","first-page":"e272","DOI":"10.1097\/TP.0000000000003849","article-title":"Obinutuzumab in kidney transplantation: effect on B-cell counts and crossmatch tests","volume":"105","author":"Zhang","year":"2021","journal-title":"Transplantation"},{"issue":"1","key":"2026032401014230900_zxaf300-B19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13317-017-0100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immune Highlights"},{"issue":"5","key":"2026032401014230900_zxaf300-B20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1007\/s10067-020-04996-7","article-title":"Effects of rituximab therapy on B cell differentiation and depletion","volume":"39","author":"Bergantini","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"9","key":"2026032401014230900_zxaf300-B21","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/TP.0b013e3181d21e7f","article-title":"Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation","volume":"89","author":"Vo","year":"2010","journal-title":"Transplantation"},{"issue":"8","key":"2026032401014230900_zxaf300-B22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1097\/TP.0b013e31820f08e8","article-title":"The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction","volume":"91","author":"Fuchinoue","year":"2011","journal-title":"Transplantation"},{"issue":"5","key":"2026032401014230900_zxaf300-B23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1182\/blood-2017-03-771832","article-title":"Obinutuzumab: what is there to learn from clinical trials?","volume":"130","author":"Cartron","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2026032401014230900_zxaf300-B24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000381524","article-title":"Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-Hodgkin\u2019s lymphomas: a glycoengineered type II CD20 antibody","volume":"38","author":"Goede","year":"2015","journal-title":"Oncol Res Treat"},{"issue":"2","key":"2026032401014230900_zxaf300-B25","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/TP.0000000000003686","article-title":"Obinutuzumab in kidney transplantation: effect on B-cell counts and crossmatch tests","volume":"106","author":"NasrAllah","year":"2022","journal-title":"Transplantation"},{"issue":"suppl 3","key":"2026032401014230900_zxaf300-B26","article-title":"Experience with obinutuzumab (type II anti-CD20) in kidney transplant patients with donor specific antibody (DSA+) antibody mediated rejection. Abstract","author":"Choi","year":"2017","journal-title":"Am J Transplant"},{"issue":"2","key":"2026032401014230900_zxaf300-B27","doi-asserted-by":"publisher","first-page":"e1436","DOI":"10.1097\/TXD.0000000000001436","article-title":"Obinutuzumab effectively depletes key B-cell subsets in blood and tissue in end-stage renal disease patients","volume":"9","author":"Looney","year":"2023","journal-title":"Transplant Direct"},{"key":"2026032401014230900_zxaf300-B28","doi-asserted-by":"publisher","first-page":"110240","DOI":"10.1016\/j.clim.2024.110240","article-title":"Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: a proof of concept","volume":"264","author":"Favi","year":"2024","journal-title":"Clin Immunol"},{"key":"2026032401014230900_zxaf300-B29","author":"Roche"},{"issue":"1","key":"2026032401014230900_zxaf300-B30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/all.14984","article-title":"Hypersensitivity reactions to biologicals: an EAACI position paper","volume":"77","author":"Bavbek","year":"2022","journal-title":"Allergy"},{"issue":"2","key":"2026032401014230900_zxaf300-B31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3904\/kjim.2021.438","article-title":"Desensitization for the prevention of drug hypersensitivity reactions","volume":"37","author":"Kang","year":"2022","journal-title":"Korean J Intern Med"},{"key":"2026032401014230900_zxaf300-B32","doi-asserted-by":"publisher","first-page":"1205345","DOI":"10.3389\/falgy.2023.1205345","article-title":"Editorial: diagnosis and management of allergy to chemotherapy and biologics","volume":"4","author":"Madrigal-Burgaleta","year":"2023","journal-title":"Front Allergy"},{"issue":"6","key":"2026032401014230900_zxaf300-B33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5500\/wjt.v9.i6.103","article-title":"Therapeutic apheresis in kidney transplantation: an updated review","volume":"9","author":"Salvadori","year":"2019","journal-title":"World J Transplant"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf300\/65043526\/zxaf300.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/7\/e246\/65043526\/zxaf300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/7\/e246\/65043526\/zxaf300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:02:41Z","timestamp":1774328561000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/7\/e246\/8306992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,10,30]]},"published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf300","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,1]]},"published":{"date-parts":[[2025,10,30]]}}}